Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC
Abstract
:Simple Summary
Abstract
1. Introduction
1.1. The Immune System and Immune Checkpoint Inhibitors (ICIs)
1.2. The Rationale for the Association of Immunotherapy and Surgical or Locoregional Treatments
2. Methods
2.1. Ongoing Trials Evaluating Immune Checkpoint Inhibition before Curative Treatment Modalities
2.2. Ongoing Trials Evaluating Immune Checkpoint Inhibition after Curative Treatment Modalities
2.3. Ongoing Trials Evaluating Immune Checkpoint Inhibitors in Intermediate Stage
2.4. Ongoing Trials Evaluating Immune Checkpoint Inhibitors in Combination with Transarterial Treatments
3. Conclusions and Future Perspective
Author Contributions
Funding
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- European Association for the Study of the Liver. Electronic address: [email protected]; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018, 69, 182–236, Erratum in J. Hepatol. 2019, 70, 817. [Google Scholar] [CrossRef] [Green Version]
- Bruix, J.; Reig, M.; Sherman, M. Evidence-Based Diagnosis, Staging, and Treatment of Patients with Hepatocellular Carcinoma. Gastroenterology 2016, 150, 835–853. [Google Scholar] [CrossRef] [Green Version]
- Wörns, M.A.; Galle, P.R. Patient prioritisation in HCC treatment: All (good) things come in threes. J. Hepatol. 2018, 68, 1311–1312. [Google Scholar] [CrossRef]
- Takayasu, K.; Arii, S.; Ikai, I.; Omata, M.; Okita, K.; Ichida, T.; Matsuyama, Y.; Nakanuma, Y.; Kojiro, M.; Liver Cancer Study Group of Japan; et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006, 131, 461–469. [Google Scholar] [CrossRef] [PubMed]
- Hsu, K.F.; Chu, C.H.; Chan, D.C.; Yu, J.C.; Shih, M.L.; Hsieh, H.F.; Hsieh, T.Y.; Yu, C.Y.; Hsieh, C.B. Superselective transarterial chemoembolization vs. hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function. Eur. J. Radiol. 2012, 81, 466–471. [Google Scholar] [CrossRef] [PubMed]
- Forner, A.; Reig, M.; Bruix, J. Hepatocellular carcinoma. Lancet 2018, 391, 1301–1314. [Google Scholar] [CrossRef]
- Reig, M.; Darnell, A.; Forner, A.; Rimola, J.; Ayuso, C.; Bruix, J. Systemic therapy for hepatocellular carcinoma: The issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. Semin. Liver Dis. 2014, 34, 444–455. [Google Scholar] [CrossRef]
- Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; SHARP Investigators Study Group; et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 378–390. [Google Scholar] [CrossRef] [Green Version]
- Kudo, M.; Finn, R.S.; Qin, S.; Han, K.H.; Ikeda, K.; Piscaglia, F.; Baron, A.; Park, J.W.; Han, G.; Jassem, J.; et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 2018, 391, 1163–1173. [Google Scholar] [CrossRef] [Green Version]
- Bruix, J.; Qin, S.; Merle, P.; Granito, A.; Huang, Y.H.; Bodoky, G.; Pracht, M.; Yokosuka, O.; Rosmorduc, O.; RESORCE Investigators; et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017, 389, 56–66, Erratum in Lancet 2017, 389, 36. [Google Scholar] [CrossRef] [Green Version]
- Abou-Alfa, G.K.; Meyer, T.; Cheng, A.L.; El-Khoueiry, A.B.; Rimassa, L.; Ryoo, B.Y.; Cicin, I.; Merle, P.; Chen, Y.; Park, J.W.; et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N. Engl. J. Med. 2018, 379, 54–63. [Google Scholar] [CrossRef] [PubMed]
- Zhu, A.X.; Kang, Y.K.; Yen, C.J.; Finn, R.S.; Galle, P.R.; Llovet, J.M.; Assenat, E.; Brandi, G.; Pracht, M.; REACH-2 study investigators; et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019, 20, 282–296. [Google Scholar] [CrossRef]
- Prieto, J.; Melero, I.; Sangro, B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2015, 12, 681–700. [Google Scholar] [CrossRef] [PubMed]
- Finn, R.S.; Qin, S.; Ikeda, M.; Galle, P.R.; Ducreux, M.; Kim, T.Y.; Kudo, M.; Breder, V.; Merle, P.; IMbrave150 Investigators; et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 2020, 382, 1894–1905. [Google Scholar] [CrossRef]
- Abou-Alfa, G.K.; Chan, S.L.; Kudo, M.; Lau, G.; Kelley, R.K.; Furuse, J.; Sukeepaisarnjaroen, W.; Kang, Y.-K.; Dao, T.V.; De Toni, E.N.; et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J. Clin. Oncol. 2022, 40 (Suppl. S4), 379. [Google Scholar] [CrossRef]
- Hiraoka, A.; Kumada, T.; Tada, T.; Hirooka, M.; Kariyama, K.; Tani, J.; Atsukawa, M.; Takaguchi, K.; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan); et al. Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria—Multicenter analysis. Hepatol. Res. 2022, 52, 308–316. [Google Scholar] [CrossRef]
- Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science 2011, 331, 1565–1570. [Google Scholar] [CrossRef] [Green Version]
- Makarova-Rusher, O.V.; Medina-Echeverz, J.; Duffy, A.G.; Greten, T.F. The yin and yang of evasion and immune activation in HCC. J. Hepatol. 2015, 62, 1420–1429. [Google Scholar] [CrossRef] [Green Version]
- Tumeh, P.C.; Harview, C.L.; Yearley, J.H.; Shintaku, I.P.; Taylor, E.J.; Robert, L.; Chmielowski, B.; Spasic, M.; Henry, G.; Ciobanu, V.; et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515, 568–571. [Google Scholar] [CrossRef]
- Okusaka, T.; Ikeda, M. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. ESMO Open 2018, 3, e000455. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ribas, A.; Wolchok, J.D. Cancer immunotherapy using checkpoint blockade. Science 2018, 359, 1350–1355. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nguyen, P.H.D.; Ma, S.; Phua, C.Z.J.; Kaya, N.A.; Lai, H.L.H.; Lim, C.J.; Lim, J.Q.; Wasser, M.; Lai, L.; Tam, W.L.; et al. Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. Nat. Commun. 2021, 12, 227, Erratum in Nat. Commun. 2021, 12, 1372. [Google Scholar] [CrossRef]
- Rotte, A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J. Exp. Clin. Cancer Res. 2019, 38, 255. [Google Scholar] [CrossRef] [PubMed]
- Pinato, D.J. Role of immuno-oncology beyond advanced HCC. In Proceedings of the HCC-TAG Conference 2021, Virtual, Park City, UT, USA, 26–27 March 2021. [Google Scholar]
- Bruix, J.; Takayama, T.; Mazzaferro, V.; Chau, G.Y.; Yang, J.; Kudo, M.; Cai, J.; Poon, R.T.; Han, K.H.; STORM investigators; et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015, 16, 1344–1354. [Google Scholar] [CrossRef]
- Greten, T.F.; Mauda-Havakuk, M.; Heinrich, B.; Korangy, F.; Wood, B.J. Combined locoregional-immunotherapy for liver cancer. J. Hepatol. 2019, 70, 999–1007. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhuang, X. Effects of microwave ablation on T-cell subsets and cytokines of patients with hepatocellular carcinoma. Minim. Invasive Ther. Allied Technol. 2017, 26, 207–211. [Google Scholar] [CrossRef]
- Ayaru, L.; Pereira, S.P.; Alisa, A.; Pathan, A.A.; Williams, R.; Davidson, B.; Burroughs, A.K.; Meyer, T.; Behboudi, S. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J. Immunol. 2007, 178, 1914–1922. [Google Scholar] [CrossRef] [Green Version]
- Nobuoka, D.; Motomura, Y.; Shirakawa, H.; Yoshikawa, T.; Kuronuma, T.; Takahashi, M.; Nakachi, K.; Ishii, H.; Furuse, J.; Gotohda, N.; et al. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. Int. J. Oncol. 2012, 40, 63–70. [Google Scholar] [CrossRef] [Green Version]
- Chew, V.; Lee, Y.H.; Pan, L.; Nasir, N.J.M.; Lim, C.J.; Chua, C.; Lai, L.; Hazirah, S.N.; Lim, T.K.H.; Goh, B.K.P.; et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut 2019, 68, 335–346. [Google Scholar] [CrossRef]
- Liang, P.; Dong, B.; Yu, X.; Yu, D.; Wang, Y.; Feng, L.; Xiao, Q. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology 2005, 235, 299–307. [Google Scholar] [CrossRef] [PubMed]
- Duan, X.; Wang, M.; Han, X.; Ren, J.; Huang, G.; Ju, S.; Zhang, Q. Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice. Cell Cycle. 2020, 19, 3595–3607. [Google Scholar] [CrossRef] [PubMed]
- Lee, J.H.; Lee, J.H.; Lim, Y.S.; Yeon, J.E.; Song, T.J.; Yu, S.J.; Gwak, G.Y.; Kim, K.M.; Kim, Y.J.; Lee, J.W.; et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015, 148, 1383–1391.e6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Takayama, T.; Sekine, T.; Makuuchi, M.; Yamasaki, S.; Kosuge, T.; Yamamoto, J.; Shimada, K.; Sakamoto, M.; Hirohashi, S.; Ohashi, Y.; et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 2000, 356, 802–807, Erratum in: Lancet 2000, 356, 1690. [Google Scholar] [CrossRef]
- Duffy, A.G.; Ulahannan, S.V.; Makorova-Rusher, O.; Rahma, O.; Wedemeyer, H.; Pratt, D.; Davis, J.L.; Hughes, M.S.; Heller, T.; ElGindi, M.; et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J. Hepatol. 2017, 66, 545–551. [Google Scholar] [CrossRef] [Green Version]
- Xing, R.; Gao, J.; Cui, Q.; Wang, Q. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Front. Immunol. 2021, 12, 783236. [Google Scholar] [CrossRef]
- Hiroishi, K.; Eguchi, J.; Baba, T.; Shimazaki, T.; Ishii, S.; Hiraide, A.; Sakaki, M.; Doi, H.; Uozumi, S.; Omori, R.; et al. Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J. Gastroenterol. 2010, 45, 451–458. [Google Scholar] [CrossRef]
- Huang, A.C.; Postow, M.A.; Orlowski, R.J.; Mick, R.; Bengsch, B.; Manne, S.; Xu, W.; Harmon, S.; Giles, J.R.; Wenz, B.; et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 2017, 545, 60–65. [Google Scholar] [CrossRef] [Green Version]
- Leppelmann, K.S.; Mooradian, M.J.; Ganguli, S.; Uppot, R.N.; Yamada, K.; Irani, Z.; Wehrenberg-Klee, E.P.; Zubiri, L.; Reynolds, K.L.; Arellano, R.S.; et al. Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis. J. Vasc. Interv. Radiol. 2021, 32, 187–195. [Google Scholar] [CrossRef]
- Pinato, D.J.; Cortellini, A.; Sukumaran, A.; Cole, T.; Pai, M.; Habib, N.; Spalding, D.; Sodergren, M.H.; Martinez, M.; Dhillon, T.; et al. PRIME-HCC: Phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. BMC Cancer 2021, 21, 301. [Google Scholar] [CrossRef]
- Pinato, D.J.; Fessas, P.; Sapisochin, G.; Marron, T.U. Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma. Hepatology 2021, 74, 483–490. [Google Scholar] [CrossRef] [PubMed]
- Zhang, W.; Zhang, B.; Chen, X.P. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front. Med. 2021, 15, 155–169. [Google Scholar] [CrossRef] [PubMed]
- A Study of Nivolumab in Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative 7hepatic Resection or Ablation (CheckMate 9DX). ClinicalTrials.gov. Posted 26 December 2017. Updated 10 February 2021. Available online: https://clinicaltrials.gov/ct2/show/NCT03383458 (accessed on 26 March 2021).
- A Study of Atezolizumab plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence after Surgical Resection or Ablation (IMbrave050). ClinicalTrials.gov. Posted 25 September 2019. Updated 5 March 2021. Available online: https://www.clinicaltrials.gov/ct2/show/NCT04102098 (accessed on 26 March 2021).
- Assess Efficacy and Safety of Durvalumab Alone or Combined with Bevacizumab in High Risk of Recurrence HCC Patients after Curative Treatment (EMERALD-2). ClinicalTrials.gov. Posted 20 February 2019. Updated 22 March 2021. Available online: https://clinicaltrials.gov/ct2/show/NCT03847428 (accessed on 26 March 2021).
- Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma (HCC) and Complete Radiological Response after Surgical Resection or Local Ablation (MK-3475-937/KEYNOTE-937). ClinicalTrials.gov. Posted 7 March 2019. Updated 22 March 2021. Available online: https://clinicaltrials.gov/ct2/show/NCT03867084 (accessed on 26 March 2021).
- Tai, D.; Loke, K.; Gogna, A.; Kaya, N.A.; Tan, S.H.; Hennedige, T.; Ng, D.; Irani, F.; Lee, J.; Lim, J.Q.; et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): A single arm, single centre, phase 2 trial. Lancet Gastroenterol. Hepatol. 2021, 6, 1025–1035. [Google Scholar] [CrossRef]
Identifier | Agent | Study Type | Outcome Measures | Recruitment Status | Primary Completion Date |
---|---|---|---|---|---|
NCT04965714 | Nivolumab and Pegargiminase Before Resectable HCC | Interventional Phase 2 | AEs Rate of pathologic CR | Not yet recruiting | 31 March 2022 |
NCT03299946 | Feasibility and Efficacy of Cabozantinib Plus Nivolumab (CaboNivo) Followed by Resection | Interventional Phase 1 | AEs Number of patients who complete pre-op treatment and proceed to surgery | Active, not recruiting | 9 December 2019 |
NCT03682276 | Safety and Bioactivity of Ipilimumab and Nivolumab Before Resection HCC | Interventional Phase 1, 2 | Delay to surgery AEs | Recruiting | 1 September 2022 |
NCT03630640 | Neoadjuvant Nivolumab with Electroporation | Interventional Phase 2 | RFS Recurrence rate | Recruiting | November 2023 |
NCT03299946 | Feasibility and Efficacy of Cabozantinib Plus Nivolumab (CaboNivo) Followed by Resection | Interventional Phase 1 | AEs Number of patients who complete pre-op treatment and proceed to surgery | Active, not recruiting | 9 December 2019 |
NCT04658147 | Nivolumab With or Without Relatlimab in Resectable HCC | Phase 1 | Number of patients who complete pre-op treatment and proceed to surgery | Recruiting | 1 June 2025 |
NCT04721132 | Atezolizumab and Bevacizumab Before Surgery | Interventional Phase 2 | pCR rate AEs | Not yet recruiting | 30 December 2022 |
NCT04380545 | Nivolumab, Fluorouracil, and Interferon Alpha 2B for Unresectable Fibrolamellar Cancer | Interventional Phase 1–2 | AEs | recruiting | 20 July 2023 |
NCT03337841 | Pembrolizumab in preventing recurrence before surgery or ablation | Interventional Phase 2 | One-year RFS | Unknown | 31 October 2019 |
Identifier | Agent | Study Type | Outcome Measures | Recruitment Status | Primary Completion Date |
---|---|---|---|---|---|
NCT03847428 | Assess Efficacy and Safety of Durvalumab Alone or plus Bevacizumab After Curative Treatment (EMERALD-2) | Interventional Phase 3 | RFS | Recruiting | 31 May 2023 |
NCT03859128 | Toripalimab or Placebo After Radical Resection (JUPITER 04) | Interventional Phase 2, 3 | RFS | Active, not recruiting | 18 April 2023 |
NCT03383458 | Nivolumab After Resection or Ablation | Interventional Phase 3 | RFS OS TTR | Active, not recruiting | 16 January 2023 |
NCT03630640 | Adjuvant Nivolumab with Electroporation | Interventional Phase 2 | RFS Recurrence rate | Recruiting | November 2023 |
NCT04981665 | TACE Sequential Tislelizumab as Adjuvant Therapy After Curative Resection | Interventional Phase 2 | 2-year RFS Rate | Recruiting | December 2024 |
NCT04102098 | Atezolizumab plus bevacizumab After resected or ablated HCC | Interventional Phase 3 | RFS | Active, not recruiting | 28 September 2023 |
NCT03867084 | Safety and Efficacy of Pembrolizumab Versus Placebo After Surgical Resection or Local Ablation (MK-3475-937/KEYNOTE-937) | Interventional Phase 3 | RFS OS | Recruiting | 30 June 2025 |
NCT04682210 | Sintilimab Plus Bevacizumab After Curative Resection | Interventional Phase 3 | RFS | Not yet recruiting | December 2023 |
Identifier | Agent | Study Type | Endpoints | Recruitment Status | Primary Completion Date |
---|---|---|---|---|---|
NCT04777851 | Regorafenib plus Nivolumab Versus TACE in Beyond Up-to-7 (RENOTACE) | Interventional Phase 3 | PFS | Recruiting | 15 December 2024 |
NCT04803994 | Efficacy and safety of atezolizumab plus bevacizumab plus TACE Versus TACE (ABC-HCC) | Interventional Phase 2 | Time to failure of treatment strategy | Recruiting | 1 April 2023 |
Identifier | Agent | Study Type | Endpoints | Recruitment Status | Primary Completion Date |
---|---|---|---|---|---|
NCT04174781 | Neoadjuvant Therapy for Hepatocellular Carcinoma | Interventional Phase 2 | PFS | Recruiting | 30 November 2020 |
NCT04268888 | Nivolumab plus TACE/TAE (TACE-3) | Interventional Phase 2–3 | OS TTTP | Recruiting | June 2025 |
NCT04340193 | Nivolumab and Ipilimumab plus TACE (CheckMate 74W) | Interventional Phase 3 | TTTP OS | Active, not recruiting | 28 January 2024 |
NCT04229355 | DEB-TACE plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable HCC | Interventional Phase 3 | PFS | Recruiting | 30 December 2022 |
NCT04246177 | Lenvatinib and pembrolizumab plus TACE | Interventional Phase 3 | PFS OS | Recruiting | 25 April 2025 |
NCT04472767 | Cabozantinib plus Ipilimumab/Nivolumab and TACE | Interventional Phase 2 | Percentage of Participants with PFS CRR | Recruiting | 1 March 2022 |
NCT04975932 | Efficacy and Safety of TACE plus ICIs | Observational | PFS | Recruiting | 1 October 2021 |
NCT04522544 | Durvalumab (MEDI4736) and Tremelimumab plus Y-90 SIRT or TACE | Interventional Phase 2 | ORR at 6 months | Recruiting | 31 March 2024 |
NCT04988945 | TACE and SBRT followed by Durvalumab or Tremelimumab | Interventional Phase 2 | Downstaging for hepatectomy | Recruiting | 1 December 2022 |
NCT03638141 | Durvalumab and Tremelimumab Following DEB-TACE | Interventional Phase 2 | ORR | Recruiting | November 2023 |
NCT03572582 | TACE plus Nivolumab | Interventional Phase 2 | ORR | Active, not recruiting | June 2023 |
NCT03033446 | Y90-Radioembolization plus Nivolumab | Interventional Phase 2 | RR | Active, not recruiting | December 2021 |
NCT03778957 | TACE plus Durvalumab and Bevacizumab (EMERALD-1) | Interventional Phase 3 | PFS | Recruiting | 19 September 2022 |
NCT03397654 | Pembrolizumab Following TACE (PETAL) | Interventional Phase 1b | AEs | Recruiting | 31 December 2021 |
NCT05063565 | TheraSphere +/− Durvalumab and Tremelimumab (ROWAN) | Interventional Phase 2 | ORR Complete response and partial response DoR | Not yet recruiting | June 2025 |
NCT04712643 | Efficacy and Safety of atezolizumab plus bevacizumab plus TACE Versus TACE | Interventional Phase 3 | TACE PFS OS | Recruiting | 28 February 2025 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Marzi, L.; Mega, A.; Gitto, S.; Pelizzaro, F.; Seeber, A.; Spizzo, G. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC. Cancers 2022, 14, 3332. https://doi.org/10.3390/cancers14143332
Marzi L, Mega A, Gitto S, Pelizzaro F, Seeber A, Spizzo G. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC. Cancers. 2022; 14(14):3332. https://doi.org/10.3390/cancers14143332
Chicago/Turabian StyleMarzi, Luca, Andrea Mega, Stefano Gitto, Filippo Pelizzaro, Andreas Seeber, and Gilbert Spizzo. 2022. "Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC" Cancers 14, no. 14: 3332. https://doi.org/10.3390/cancers14143332